ImmunID Technologies is an innovative company offering diagnostic and prognostic tools to contribute to define immune signatures and monitor immuno-regulation status to delineating stages of a disease progression and to choosing, adjusting and following appropriate therapies. ImmunID services contribute to the selection and development of the best molecules or vaccines to help pharmaceuticals companies measure their efficiency.
ImmunID strives to develop gold standard tools for monitoring the immune cell repertoire. Thanks to genome sequencing and immunogenetics, it is possible to study the genes that form the basis of immune repertoire diversity. ImmunID has developed technologies to diagnose subtle changes in the immune repertoire at an early stage.